289 related articles for article (PubMed ID: 25948101)
21. Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults.
Hopkins SC; Sunkaraneni S; Skende E; Hing J; Passarell JA; Loebel A; Koblan KS
Clin Drug Investig; 2016 Feb; 36(2):137-46. PubMed ID: 26597180
[TBL] [Abstract][Full Text] [Related]
22. Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe.
Coghill DR; Banaschewski T; Nagy P; Otero IH; Soutullo C; Yan B; Caballero B; Zuddas A
CNS Drugs; 2017 Jul; 31(7):625-638. PubMed ID: 28667569
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
[TBL] [Abstract][Full Text] [Related]
24. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of a Long-Acting Multilayer-Release Methylphenidate Formulation (PRC-063) in the Treatment of Adolescent Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Clinical Trial with a 6-Month Open-Label Extension.
Weiss MD; Cutler AJ; Kollins SH; Donnelly GAE
J Child Adolesc Psychopharmacol; 2021 Nov; 31(9):610-622. PubMed ID: 34637343
[No Abstract] [Full Text] [Related]
26. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
Findling RL; Childress AC; Cutler AJ; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179
[TBL] [Abstract][Full Text] [Related]
27. Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
Wigal T; Brams M; Gasior M; Gao J; Giblin J
Postgrad Med; 2011 Mar; 123(2):169-76. PubMed ID: 21474905
[TBL] [Abstract][Full Text] [Related]
28. A Randomized, Placebo-Controlled Laboratory Classroom Study of the Efficacy and Safety of Dasotraline in Children With ADHD.
Wigal S; Tsai J; Bates JA; Sarma K; Tortorich D; Zhu H; Goldman R
J Atten Disord; 2022 Aug; 26(10):1357-1368. PubMed ID: 35048745
[TBL] [Abstract][Full Text] [Related]
29. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.
Adler LA; Spencer T; Brown TE; Holdnack J; Saylor K; Schuh K; Trzepacz PT; Williams DW; Kelsey D
J Clin Psychopharmacol; 2009 Feb; 29(1):44-50. PubMed ID: 19142107
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study.
Jain U; Hechtman L; Weiss M; Ahmed TS; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
J Clin Psychiatry; 2007 Feb; 68(2):268-77. PubMed ID: 17335326
[TBL] [Abstract][Full Text] [Related]
31. A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study.
Biederman J; Swanson JM; Wigal SB; Boellner SW; Earl CQ; Lopez FA;
J Clin Psychiatry; 2006 May; 67(5):727-35. PubMed ID: 16841622
[TBL] [Abstract][Full Text] [Related]
32. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
[TBL] [Abstract][Full Text] [Related]
33. A randomized, double-blind study of SHP465 mixed amphetamine salts extended-release in adults with ADHD using a simulated adult workplace design.
Wigal T; Brams M; Frick G; Yan B; Madhoo M
Postgrad Med; 2018 Jun; 130(5):481-493. PubMed ID: 29809075
[TBL] [Abstract][Full Text] [Related]
34. Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial.
Stein MA; Sikirica V; Weiss MD; Robertson B; Lyne A; Newcorn JH
CNS Drugs; 2015 Nov; 29(11):953-62. PubMed ID: 26547425
[TBL] [Abstract][Full Text] [Related]
35. A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
Findling RL; Cutler AJ; Saylor K; Gasior M; Hamdani M; Ferreira-Cornwell MC; Childress AC
J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):11-21. PubMed ID: 23410138
[TBL] [Abstract][Full Text] [Related]
36. A Phase 3, Randomized Double-Blind Study of the Efficacy and Safety of Low-Dose SHP465 Mixed Amphetamine Salts Extended-Release in Children with Attention-Deficit/Hyperactivity Disorder.
Mattingly G; Arnold V; Yan B; Yu M; Robertson B
J Child Adolesc Psychopharmacol; 2020 Nov; 30(9):549-557. PubMed ID: 33185468
[No Abstract] [Full Text] [Related]
37. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
Adler LA; Goodman DW; Kollins SH; Weisler RH; Krishnan S; Zhang Y; Biederman J;
J Clin Psychiatry; 2008 Sep; 69(9):1364-73. PubMed ID: 19012818
[TBL] [Abstract][Full Text] [Related]
38. Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study.
Mohammadi MR; Hafezi P; Galeiha A; Hajiaghaee R; Akhondzadeh S
Acta Med Iran; 2012; 50(11):723-8. PubMed ID: 23292622
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Lisdexamfetamine in Preschool Children With Attention-Deficit/Hyperactivity Disorder.
Childress AC; Lloyd E; Jacobsen L; Gunawardhana L; Johnson SA; Findling RL
J Am Acad Child Adolesc Psychiatry; 2022 Dec; 61(12):1423-1434. PubMed ID: 35577034
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]